Heart rate reserve during pharmacological stress is a significant negative predictor of impaired coronary flow reserve in women.


Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 14 09 2018
accepted: 04 01 2019
pubmed: 17 1 2019
medline: 21 7 2020
entrez: 17 1 2019
Statut: ppublish

Résumé

Evidence to date has failed to adequately explore determinants of cardiovascular risk in women with coronary microvascular dysfunction (CMVD). Heart rate responses to adenosine mirror autonomic activity and may carry important prognostic information for the diagnosis of CMVD. Hemodynamic changes during adenosine stress were analyzed in a propensity-matched cohort of 404 patients (202 women, mean age 65.9 ± 11.0) who underwent clinically indicated myocardial perfusion Baseline heart rate (HR) was significantly higher in patients with abnormal coronary flow reserve (CFR, p < 0.001 vs normal CFR). Accordingly, a blunted HR response to adenosine (=reduced heart rate reserve, %HRR) was seen in patients with abnormal CFR, with a most pronounced effect being observed in female patients free of myocardial ischemia (45.9 ± 34.9 vs 26.5 ± 18.0, p < 0.001 in women and 29.1 ± 16.9 vs 24.3 ± 21.7, p = 0.15 in men). Hence, a fully-adjusted multivariate logistic regression model identified HRR as the strongest negative predictor of reduced CFR in women free of myocardial ischemia, but not in men. Accordingly, receiver operating characteristics (ROC) curves for the presence of reduced CFR revealed that a %HRR <35 was a powerful predictor for abnormal CFR with a sensitivity of 81% and a specificity of 60% in women. A blunted HRR <35% is associated with abnormal CFR in women. Taking into account HR responses during stress test in women may help to risk stratify the heterogeneous female population of patients with non-obstructive coronary artery disease (CAD).

Identifiants

pubmed: 30648200
doi: 10.1007/s00259-019-4265-7
pii: 10.1007/s00259-019-4265-7
doi:

Substances chimiques

Nitrogen Isotopes 0
Nitrogen Radioisotopes 0
Radiopharmaceuticals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1257-1267

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CH)
ID : Research grant to CG
Organisme : Olga Mayenfisch Foundation
ID : Research grant to CG
Organisme : OPO-Stiftung
ID : Research grant to CG
Organisme : Novartis Stiftung für Medizinisch-Biologische Forschung
ID : Research grant to CG
Organisme : Swissheart Foundation
ID : Research grant to CG
Organisme : Helmut Horten Foundation
ID : Research grant to CG
Organisme : Iten-Kohaut Foundation
ID : Research grant to MM

Références

Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9226-33
pubmed: 10922074
Cardiovasc Res. 2001 Apr;50(1):151-61
pubmed: 11282088
Cardiovasc Res. 2001 Nov;52(2):208-16
pubmed: 11684068
Am J Cardiol. 2002 Jan 15;89(2):174-7
pubmed: 11792338
Circulation. 2003 Jun 17;107(23):2894-9
pubmed: 12796141
Circulation. 2005 Feb 8;111(5):682-96
pubmed: 15687114
Heart. 2006 May;92 Suppl 3:iii5-9
pubmed: 16614266
Am J Cardiol. 1991 Dec 15;68(17):1698-703
pubmed: 1746475
Acad Radiol. 2008 Apr;15(4):444-51
pubmed: 18342769
Am J Cardiol. 2008 Oct 15;102(8):1103-6
pubmed: 18929717
Am Heart J. 2009 Apr;157(4):771-6
pubmed: 19332209
Circulation. 2009 Jun 9;119(22):e561-87
pubmed: 19451357
J Am Coll Cardiol. 2009 Jul 7;54(2):150-6
pubmed: 19573732
Am J Cardiol. 2010 Mar 15;105(6):839-43
pubmed: 20211328
J Am Coll Cardiol. 1991 Jun;17(7):1461-70
pubmed: 2033177
J Nucl Med. 2010 Jul;51(7):1036-43
pubmed: 20554740
J Am Coll Cardiol. 2010 Jun 22;55(25):2825-32
pubmed: 20579539
J Nucl Cardiol. 2011 Dec;18(6):1086-94
pubmed: 21785922
Circulation. 2011 Nov 15;124(20):2215-24
pubmed: 22007073
Int J Cardiol. 2013 Aug 10;167(3):1023-6
pubmed: 22475847
J Am Coll Cardiol. 2012 May 8;59(19):1719-28
pubmed: 22554604
Imaging Med. 2013 Feb 1;5(1):35-46
pubmed: 23671459
J Nucl Med. 2013 Aug;54(8):1485-507
pubmed: 23781013
Am Heart J. 2013 Jul;166(1):38-44
pubmed: 23816019
Eur Heart J Cardiovasc Imaging. 2014 Jun;15(6):659-65
pubmed: 24408930
Circulation. 2014 Jun 17;129(24):2518-27
pubmed: 24787469
Int J Cardiovasc Imaging. 2015 Jun;31(5):1089-95
pubmed: 25846547
Nat Rev Cardiol. 2015 Jul;12(7):406-14
pubmed: 26011377
Circulation. 2015 Sep 15;132(11):997-1002
pubmed: 26302759
J Am Coll Cardiol. 2015 Oct 27;66(17):1918-33
pubmed: 26493665
Heart Fail Clin. 2016 Jan;12(1):141-56
pubmed: 26567981
Circulation. 1989 Jul;80(1):87-98
pubmed: 2661056
JACC Cardiovasc Imaging. 2016 Apr;9(4):421-35
pubmed: 27056162
Eur Heart J. 2016 Nov 7;37(42):3232-3245
pubmed: 27523477
J Nucl Cardiol. 2018 Apr 23;:null
pubmed: 29687292
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1964-1974
pubmed: 29779046
PLoS One. 2018 Aug 14;13(8):e0202302
pubmed: 30106984
Acta Physiol Scand. 1987 Dec;131(4):525-31
pubmed: 3327362
Radiology. 1988 Sep;168(3):878-9
pubmed: 3406418
J Am Coll Cardiol. 1993 Nov 15;22(6):1607-13
pubmed: 8227827
J Am Coll Cardiol. 1996 Nov 1;28(5):1214-9
pubmed: 8890818
Am J Cardiol. 1997 Jul 15;80(2):132-7
pubmed: 9230147
Am J Cardiol. 1998 Sep 15;82(6):725-30
pubmed: 9761081

Auteurs

Ahmed Haider (A)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.
Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland.

Susan Bengs (S)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.
Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland.

Monika Maredziak (M)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.
Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland.

Michael Messerli (M)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Michael Fiechter (M)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.
Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland.

Andreas A Giannopoulos (AA)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Valerie Treyer (V)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Moritz Schwyzer (M)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Christel Hermann Kamani (CH)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Dimitri Patriki (D)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Elia von Felten (E)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Dominik C Benz (DC)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Tobias A Fuchs (TA)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Christoph Gräni (C)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Aju P Pazhenkottil (AP)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Philipp A Kaufmann (PA)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Ronny R Buechel (RR)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

Catherine Gebhard (C)

Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland. Catherine.gebhard@usz.ch.
Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland. Catherine.gebhard@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH